---
layout: default
title: Atezolizumab
parent: 僅模型預測 (L5)
nav_order: 46
evidence_level: L5
indication_count: 10
---

# Atezolizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ATEZOLIZUMAB: Repurposing Evaluation — Insufficient Data to Proceed

## One-Sentence Summary

ATEZOLIZUMAB (DrugBank ID: DB11595) is a drug for which no original indication or mechanism of action data is available in the current Evidence Pack.
No TxGNN predicted indications have been generated, and the drug is not currently marketed in Finland.
This evaluation cannot be completed without further data collection.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | Not available |
| Evidence Level | N/A — no predictions generated |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN predicted indications are available for ATEZOLIZUMAB in this Evidence Pack. The `predicted_indications` field is empty, meaning no repurposing candidates have been generated for evaluation. Without a predicted indication, the central question of this report — whether the drug can be repositioned — cannot be addressed.

Mechanism of action data is also absent. MOA information is required to establish any mechanistic rationale linking a known pharmacological action to a new therapeutic target. Without it, even qualitative plausibility arguments cannot be formed.

Finally, ATEZOLIZUMAB has no approved product in Finland (0 authorizations, market status: not marketed), which means there is no local regulatory baseline against which to assess a repurposing extension.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this evaluation.

---

## Literature Evidence

Currently no related literature available for this evaluation.

---

## Finland Market Information

ATEZOLIZUMAB is not currently marketed in Finland. No product authorizations are on file.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for ATEZOLIZUMAB is critically incomplete across all evaluation dimensions — predicted indications, mechanism of action, original indication, and safety data are all missing. A meaningful repurposing assessment cannot be conducted in the current state.

**To proceed, the following is needed:**

- **TxGNN prediction results**: `predicted_indications` must be populated before any repurposing direction can be evaluated
- **Mechanism of action (MOA)**: Query DrugBank API (DB11595) to retrieve pharmacological action and drug class data
- **Original indication**: Retrieve from Fimea product registry or reference labelling from EMA/FDA
- **Safety information**: Download and parse the package insert PDF to extract warnings, contraindications, and special population precautions
- **Drug-drug interaction data**: Re-query DDI database; current result is `not_found` with 0 interactions returned
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

